Jennifer Kayden Lee has sold RYTM and made no open-market buys since Aug 2023

Lee Jennifer Kayden is a corporate insider and senior executive serving as Executive Vice President, Head of North America at Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), where she is an officer responsible for leading the company’s commercial and strategic operations across the North American market.( In this role, she plays a key part in shaping Rhythm’s growth trajectory in rare genetic obesity, and her insider activity, including equity awards and share sales reported on multiple Form 4 filings, reflects her ongoing participation in the company’s long‑term incentive and ownership programs.(

Professionally, she is also known as Jennifer Lee, an entrepreneurial pharmaceutical executive with broad experience in strategy development and implementation, business and corporate development, new product planning, commercialization, and market access in both global and U.S. markets.( Before joining Rhythm Pharmaceuticals in November 2020, she served as Chief Commercial Officer at Krystal Biotech, Inc. and previously held leadership roles at Sanofi Genzyme, including Vice President, Head of Genetic Diseases for U.S. Rare Diseases.( Lee earned a B.A. in Biology from the Massachusetts Institute of Technology and an M.S. in Health Policy and Management from Harvard University, providing a strong scientific and health policy foundation for her executive leadership in the biopharmaceutical industry.(

Written by Perplexity from public sources.